MX2010005298A - Compuestos de carboxamida, sulfonamida y amina para trastornos metabolicos. - Google Patents
Compuestos de carboxamida, sulfonamida y amina para trastornos metabolicos.Info
- Publication number
- MX2010005298A MX2010005298A MX2010005298A MX2010005298A MX2010005298A MX 2010005298 A MX2010005298 A MX 2010005298A MX 2010005298 A MX2010005298 A MX 2010005298A MX 2010005298 A MX2010005298 A MX 2010005298A MX 2010005298 A MX2010005298 A MX 2010005298A
- Authority
- MX
- Mexico
- Prior art keywords
- sulfonamide
- carboxamide
- amine compounds
- metabolic disorders
- compound
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/44—Oxygen atoms attached in position 4
- C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
- C07D211/58—Nitrogen atoms attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Hydrogenated Pyridines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US98872107P | 2007-11-16 | 2007-11-16 | |
| US99055807P | 2007-11-27 | 2007-11-27 | |
| US99055407P | 2007-11-27 | 2007-11-27 | |
| US99118907P | 2007-11-29 | 2007-11-29 | |
| US1392407P | 2007-12-14 | 2007-12-14 | |
| PCT/US2008/083801 WO2009065131A1 (en) | 2007-11-16 | 2008-11-17 | Carboxamide, sulfonamide and amine compounds for metabolic disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2010005298A true MX2010005298A (es) | 2010-06-30 |
Family
ID=40352415
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2010005298A MX2010005298A (es) | 2007-11-16 | 2008-11-17 | Compuestos de carboxamida, sulfonamida y amina para trastornos metabolicos. |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US8119809B2 (ko) |
| EP (1) | EP2231600B1 (ko) |
| JP (1) | JP5544296B2 (ko) |
| KR (1) | KR101573091B1 (ko) |
| CN (1) | CN101910131B (ko) |
| AU (3) | AU2008322426C1 (ko) |
| BR (1) | BRPI0820171B8 (ko) |
| CA (1) | CA2705947C (ko) |
| EA (1) | EA019509B1 (ko) |
| ES (1) | ES2552733T3 (ko) |
| HK (1) | HK1148525A1 (ko) |
| IL (1) | IL205624A (ko) |
| MX (1) | MX2010005298A (ko) |
| NZ (1) | NZ585298A (ko) |
| WO (1) | WO2009065131A1 (ko) |
| ZA (1) | ZA201003412B (ko) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2627221T3 (es) | 2006-12-28 | 2017-07-27 | Rigel Pharmaceuticals, Inc. | Compuestos de heterocicloalquiloxibenzamida N-sustituidos y métodos de uso |
| ES2552733T3 (es) | 2007-11-16 | 2015-12-01 | Rigel Pharmaceuticals, Inc. | Compuestos de carboxamida, sulfonamida y amina para trastornos metabólicos |
| CA2707047C (en) * | 2007-12-12 | 2017-11-28 | Rigel Pharmaceuticals, Inc. | Carboxamide, sulfonamide and amine compounds for metabolic disorders |
| MX2010011288A (es) | 2008-04-23 | 2010-11-09 | Rigel Pharmaceuticals Inc | Compuestos de carboxamida para el tratamiento de trastornos metabolicos. |
| BRPI1006128A2 (pt) | 2009-01-12 | 2016-11-01 | Cagen Inc | derivados de sulfonamida |
| SG172974A1 (en) | 2009-01-28 | 2011-08-29 | Rigel Pharmaceuticals Inc | Carboxamide compounds and methods for using the same |
| SG176628A1 (en) | 2009-06-05 | 2012-01-30 | Link Medicine Corp | Aminopyrrolidinone derivatives and uses thereof |
| CN102666485A (zh) * | 2009-09-21 | 2012-09-12 | 霍夫曼-拉罗奇有限公司 | 烯烃羟吲哚衍生物及其用于治疗肥胖症，糖尿病和高脂血症的应用 |
| WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
| US20130274185A1 (en) * | 2010-03-16 | 2013-10-17 | The University Of Tokyo | Pharmaceutical for Pseudo-Exercise Therapy |
| US8796254B2 (en) | 2010-03-31 | 2014-08-05 | Rigel Pharmaceuticals, Inc. | Methods for using carboxamide, sulfonamide and amine compounds |
| WO2011142359A1 (ja) * | 2010-05-10 | 2011-11-17 | 日産化学工業株式会社 | スピロ化合物及びアディポネクチン受容体活性化薬 |
| US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
| TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
| TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
| TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
| US9079880B2 (en) | 2010-07-07 | 2015-07-14 | Boehringer Ingelheim International Gmbh | Rho kinase inhibitors |
| US8697911B2 (en) | 2010-07-07 | 2014-04-15 | Boehringer Ingelheim International Gmbh | Rho kinase inhibitors |
| EP2590972B1 (en) | 2010-07-09 | 2015-01-21 | Pfizer Limited | N-sulfonylbenzamides as inhibitors of voltage-gated sodium channels |
| CN103201267B (zh) | 2010-07-29 | 2016-08-17 | 里格尔药品股份有限公司 | Ampk-激活性杂环化合物以及其使用方法 |
| WO2012054367A1 (en) | 2010-10-19 | 2012-04-26 | Boehringer Ingelheim International Gmbh | Rho kinase inhibitors |
| US9005909B2 (en) | 2011-01-06 | 2015-04-14 | Rigel Pharmaceuticals, Inc. | Whole blood assay for measuring AMPK activation |
| WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| EP2760862B1 (en) | 2011-09-27 | 2015-10-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| US9409884B2 (en) | 2012-02-01 | 2016-08-09 | Rigel Pharmaceuticals, Inc. | 5- or 6-substituted benzofuran-2-carboxamide compounds and methods for using them |
| US8889730B2 (en) | 2012-04-10 | 2014-11-18 | Pfizer Inc. | Indole and indazole compounds that activate AMPK |
| US9357782B2 (en) * | 2012-08-08 | 2016-06-07 | Novartis Tiergesundheit Ag | Substituted azines as pesticides |
| US8729263B2 (en) | 2012-08-13 | 2014-05-20 | Novartis Ag | 1,4-disubstituted pyridazine analogs there of and methods for treating SMN-deficiency-related conditions |
| US9394285B2 (en) | 2013-03-15 | 2016-07-19 | Pfizer Inc. | Indole and indazole compounds that activate AMPK |
| CN105636953B (zh) | 2013-07-31 | 2018-01-02 | 诺华股份有限公司 | 1,4‑二取代的哒嗪衍生物及其用于治疗与smn缺乏相关的病症的用途 |
| JP6664632B2 (ja) * | 2013-09-30 | 2020-03-13 | 国立大学法人 東京大学 | アディポネクチン受容体活性化化合物 |
| AU2015361614B2 (en) * | 2014-12-08 | 2019-11-28 | Jiangsu Hengrui Medicine Co., Ltd. | Pyridinecarboxamide derivatives, preparation method therefor and pharmaceutical uses thereof |
| EP3959205A4 (en) * | 2019-04-26 | 2023-05-17 | Merck Sharp & Dohme LLC | METHOD FOR THE PREPARATION OF INTERMEDIATES USEFUL FOR THE MANUFACTURE OF (2S,5R)-7-OXO-N-PIPERIDIN-4-YL-6-(SULFOXY)-1,6-DIAZABICYCLO[3.2.1]OCTANE-2-CARBOXAMIDE |
| CN116322663A (zh) | 2020-09-30 | 2023-06-23 | 比奥维拉迪维治疗股份有限公司 | Ampk激活剂及其使用方法 |
Family Cites Families (69)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8820115D0 (en) | 1988-08-24 | 1988-09-28 | Ici Plc | Insecticidal compounds |
| US6137002A (en) | 1993-07-22 | 2000-10-24 | Eli Lilly And Company | Glycoprotein IIb/IIIa antagonists |
| ES2217404T3 (es) | 1996-03-28 | 2004-11-01 | Glaxo Group Limited | Derivados de pirrolopirrolona como inhibidores de la elastasa de neutrofilos. |
| GB9715584D0 (en) | 1997-07-23 | 1997-10-01 | Eisai Co Ltd | Compounds |
| DE19738615A1 (de) | 1997-09-04 | 1999-03-11 | Clariant Gmbh | Neue Lichtschutzmittel auf Basis von sterisch gehinderten Aminen |
| US6589954B1 (en) | 1998-05-22 | 2003-07-08 | Scios, Inc. | Compounds and methods to treat cardiac failure and other disorders |
| EP1107758A2 (en) | 1998-08-28 | 2001-06-20 | Scios Inc. | Use of piperidines and/or piperazines as inhibitors of p38-alpha kinase |
| US6953855B2 (en) | 1998-12-11 | 2005-10-11 | Targacept, Inc. | 3-substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof |
| KR20020038804A (ko) | 1999-10-08 | 2002-05-23 | 파퀘스, 파우쓰-베르구스 | 6원 환이 치환되어 있는 2환식 이미다조-3-일-아민 유도체 |
| US6436965B1 (en) | 2000-03-02 | 2002-08-20 | Merck Frosst Canada & Co. | PDE IV inhibiting amides, compositions and methods of treatment |
| US7273868B2 (en) | 2000-04-28 | 2007-09-25 | Tanabe Seiyaku Co., Ltd. | Pyrazine derivatives |
| WO2002000651A2 (en) | 2000-06-27 | 2002-01-03 | Bristol-Myers Squibb Pharma Company | Factor xa inhibitors |
| DE10050663A1 (de) | 2000-10-13 | 2002-04-18 | Gruenenthal Gmbh | Verwendung von substituierten Imidazo[1,2-a]pyridin-, -pyrimidin- und pyrazin-3-yl-amin-Derivaten zur Herstellung von Medikamenten zur NOS-Inhibierung |
| KR100600550B1 (ko) | 2000-10-20 | 2006-07-13 | 에자이 가부시키가이샤 | 질소 함유 방향환 유도체 |
| AU2002305552A1 (en) | 2001-05-10 | 2002-11-18 | Abbott Gmbh And Co.Kg | Arylsulfonamide ethers, and methods of use thereof |
| MXPA04000779A (es) | 2001-08-24 | 2004-04-20 | Pharmacia & Up John Company | 7-aza[2.2.1]bicicloheptanos sustituidos con arilo para el tratamiento de enfermedades. |
| JP2005527472A (ja) | 2001-09-12 | 2005-09-15 | ファルマシア・アンド・アップジョン・カンパニー・エルエルシー | 疾患治療のための置換された７−アザ［２．２．１］ビシクロヘプタン |
| CA2476681A1 (en) | 2002-02-19 | 2003-08-28 | Bruce N. Rogers | Fused bicyclic-n-bridged-heteroaromatic carboxamides for the treatment of disease |
| MXPA04007083A (es) | 2002-02-20 | 2004-10-29 | Upjohn Co | Compuestos azabiciclicos para el tratamiento de enfermedades. |
| US20040082627A1 (en) | 2002-06-21 | 2004-04-29 | Darrow James W. | Certain aromatic monocycles as kinase modulators |
| CA2493457A1 (en) * | 2002-07-24 | 2004-01-29 | Ptc Therapeutics, Inc. | Acetylamino benzoic acid compounds and their use for nonsense suppression and the treatment of disease |
| WO2004054974A2 (en) | 2002-12-13 | 2004-07-01 | Smithkline Beecham Corporation | Piperidine derivatives as ccr5 antagonists |
| US7208491B2 (en) | 2003-02-07 | 2007-04-24 | Hoffmann-La Roche Inc. | N-monoacylated o-phenylenediamines |
| GB2400101A (en) | 2003-03-28 | 2004-10-06 | Biofocus Discovery Ltd | Compounds capable of binding to the active site of protein kinases |
| GB0314054D0 (en) | 2003-06-17 | 2003-07-23 | Pfizer Ltd | Amide derivatives as selective serotonin re-uptake inhibitors |
| TWI372050B (en) | 2003-07-03 | 2012-09-11 | Astex Therapeutics Ltd | (morpholin-4-ylmethyl-1h-benzimidazol-2-yl)-1h-pyrazoles |
| WO2005020921A2 (en) | 2003-08-29 | 2005-03-10 | Exelixis, Inc. | C-kit modulators and methods of use |
| US7196100B2 (en) * | 2003-12-12 | 2007-03-27 | Eli Lilly And Company | Opioid receptor antagonists |
| US7544803B2 (en) | 2004-01-23 | 2009-06-09 | Amgen Inc. | Vanilloid receptor ligands and their use in treatments |
| CN103724343A (zh) * | 2004-03-25 | 2014-04-16 | 记忆药物公司 | 吲唑、苯并噻唑、苯并异噻唑、苯并异噁唑及其制备和用途 |
| PE20060315A1 (es) | 2004-05-24 | 2006-05-15 | Irm Llc | Compuestos de tiazol como moduladores de ppar |
| JP4594386B2 (ja) * | 2004-06-02 | 2010-12-08 | エフ．ホフマン−ラ ロシュ アーゲー | ヒスタミン３受容体のリガンドとして有用なナフタレン誘導体 |
| PL1761519T3 (pl) * | 2004-06-21 | 2008-09-30 | Hoffmann La Roche | Pochodne indolu jako antagoniści receptorów histaminowych |
| WO2006038594A1 (ja) * | 2004-10-04 | 2006-04-13 | Ono Pharmaceutical Co., Ltd. | Ｎ型カルシウムチャネル阻害薬 |
| ES2367515T3 (es) | 2004-10-19 | 2011-11-04 | F. Hoffmann-La Roche Ag | Derivados de quinolina. |
| KR20070068432A (ko) | 2004-10-29 | 2007-06-29 | 아스트라제네카 아베 | 염증 질환의 치료를 위한 글루코코르티코이드 수용체조절제로서의 신규 술폰아미드 유도체 |
| EP1813613B1 (en) | 2004-11-08 | 2012-12-19 | Msd K.K. | Novel fused imidazole derivative |
| BRPI0516915A (pt) | 2004-12-01 | 2008-03-11 | Devgen Nv | derivados de tiazol substituìdos por 5-carboxamido que interagem com canais de ìons, particularmante com canais de ìons da famìlia kv |
| WO2006076131A2 (en) | 2004-12-17 | 2006-07-20 | Smithkline Beecham Corporation | Chemical compounds |
| MX2007007345A (es) | 2004-12-17 | 2007-09-07 | Glenmark Pharmaceuticals Sa | Compuestos heterociclicos novedosos utiles para el tratamiento de trastornos inflamatorios y alergicos. |
| GB0428235D0 (en) | 2004-12-23 | 2005-01-26 | Glaxo Group Ltd | Novel compounds |
| US20060187891A1 (en) | 2005-02-24 | 2006-08-24 | Jussi-Pekka Sairanen | Provision of services in a communication system |
| EP1853590A1 (en) | 2005-03-03 | 2007-11-14 | Sirtris Pharmaceuticals, Inc. | Fused heterocyclic compounds and their use as sirtuin modulators |
| JP5066514B2 (ja) | 2005-03-14 | 2012-11-07 | ハイ ポイント ファーマシューティカルズ，エルエルシー | ベンズアゾール誘導体、組成物及びβ−セクレターゼ阻害剤としての使用方法 |
| US20100113502A1 (en) | 2005-03-22 | 2010-05-06 | Astrazeneca Ab | Novel Tetrahydro-1H-Pyrido[4,3-b] Indole Derivatives as CB1 Receptor Ligands |
| GB0508472D0 (en) | 2005-04-26 | 2005-06-01 | Glaxo Group Ltd | Compounds |
| CN101258145A (zh) | 2005-07-05 | 2008-09-03 | 阿里克斯治疗公司 | 立体异构吡啶基和吡啶酮基化合物以及治疗胃肠和中枢神经系统疾病的方法 |
| AU2006295397A1 (en) * | 2005-09-23 | 2007-04-05 | Memory Pharmaceuticals Corporation | Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, pyrazolopyridines, isothiazolopyridines, and preparation and uses thereof |
| DE602006020482D1 (de) | 2005-11-30 | 2011-04-14 | Hoffmann La Roche | 1,5-substituierte indol-2-yl amidderivative |
| DE602006014022D1 (de) | 2005-11-30 | 2010-06-10 | Hoffmann La Roche | 5-substituierte indol-2-carbonsäureamidderivate |
| CN101316838B (zh) | 2005-11-30 | 2013-01-30 | 霍夫曼-拉罗奇有限公司 | 用作h3调节剂的1,1-二氧代-硫代吗啉基吲哚基甲酮衍生物 |
| US7879880B2 (en) * | 2005-12-21 | 2011-02-01 | Schering Corporation | Substituted aniline derivatives useful as histamine H3 antagonists |
| JP2009524689A (ja) | 2006-01-25 | 2009-07-02 | スミスクライン ビーチャム コーポレーション | 化合物 |
| US20100280010A1 (en) | 2006-01-25 | 2010-11-04 | Kristjan Gudmundsson | Chemical compounds |
| WO2007098086A2 (en) * | 2006-02-17 | 2007-08-30 | Avalon Pharmaceuticals | Hydroxypiperidine derivatives and uses thereof |
| WO2007099423A1 (en) | 2006-03-02 | 2007-09-07 | Pfizer Products Inc. | 1-pyrrolidine indane derivatives as histamine-3 receptor antagonists |
| NL2000581C2 (nl) | 2006-04-20 | 2008-01-03 | Pfizer Prod Inc | Aangecondenseerde fenylamidoheterocyclische verbindingen. |
| WO2007125405A2 (en) * | 2006-05-01 | 2007-11-08 | Pfizer Products Inc. | Substituted 2-amino-fused heterocyclic compounds |
| AU2007260527A1 (en) | 2006-06-12 | 2007-12-21 | Merck Frosst Canada Ltd. | Azetidine derivatives as inhibitors of stearoyl-coenzyme A delta-9 desaturase |
| EP2032570A4 (en) | 2006-06-13 | 2010-10-27 | Merck Frosst Canada Ltd | AZACYCLOPENTATE DERIVATIVES AS INHIBITORS OF STEAROYL-COENZYME-A-DELTA-9-DESATURASE |
| TW200821303A (en) | 2006-08-08 | 2008-05-16 | Speedel Experimenta Ag | Organic compounds |
| ES2627221T3 (es) * | 2006-12-28 | 2017-07-27 | Rigel Pharmaceuticals, Inc. | Compuestos de heterocicloalquiloxibenzamida N-sustituidos y métodos de uso |
| US20100249111A1 (en) | 2007-04-26 | 2010-09-30 | Avalon Pharmaceuticals | Multi-ring compounds and uses thereof |
| BRPI0814628B1 (pt) * | 2007-07-20 | 2022-04-05 | Nerviano Medical Sciences S.R.L. | Derivados ativos de indazol substituídos como inibidores da quinase |
| ES2552733T3 (es) | 2007-11-16 | 2015-12-01 | Rigel Pharmaceuticals, Inc. | Compuestos de carboxamida, sulfonamida y amina para trastornos metabólicos |
| CA2707047C (en) * | 2007-12-12 | 2017-11-28 | Rigel Pharmaceuticals, Inc. | Carboxamide, sulfonamide and amine compounds for metabolic disorders |
| KR20100137561A (ko) * | 2008-04-07 | 2010-12-30 | 아이알엠 엘엘씨 | Ｇｐｒ119 활성의 조절제로서의 화합물 및 조성물 |
| MX2010011288A (es) * | 2008-04-23 | 2010-11-09 | Rigel Pharmaceuticals Inc | Compuestos de carboxamida para el tratamiento de trastornos metabolicos. |
| JP2010090067A (ja) * | 2008-10-09 | 2010-04-22 | Taisho Pharmaceutical Co Ltd | 含窒素複素環誘導体 |
-
2008
- 2008-11-17 ES ES08848677.4T patent/ES2552733T3/es active Active
- 2008-11-17 WO PCT/US2008/083801 patent/WO2009065131A1/en active Application Filing
- 2008-11-17 CA CA2705947A patent/CA2705947C/en active Active
- 2008-11-17 CN CN200880124960.1A patent/CN101910131B/zh active Active
- 2008-11-17 US US12/272,581 patent/US8119809B2/en active Active
- 2008-11-17 JP JP2010534263A patent/JP5544296B2/ja not_active Expired - Fee Related
- 2008-11-17 KR KR1020107013166A patent/KR101573091B1/ko active IP Right Grant
- 2008-11-17 MX MX2010005298A patent/MX2010005298A/es active IP Right Grant
- 2008-11-17 NZ NZ585298A patent/NZ585298A/xx not_active IP Right Cessation
- 2008-11-17 EA EA201070619A patent/EA019509B1/ru not_active IP Right Cessation
- 2008-11-17 BR BRPI0820171A patent/BRPI0820171B8/pt not_active IP Right Cessation
- 2008-11-17 EP EP08848677.4A patent/EP2231600B1/en active Active
- 2008-11-17 AU AU2008322426A patent/AU2008322426C1/en not_active Ceased
-
2010
- 2010-05-09 IL IL205624A patent/IL205624A/en active IP Right Grant
- 2010-05-14 ZA ZA2010/03412A patent/ZA201003412B/en unknown
-
2011
- 2011-03-16 HK HK11102635.4A patent/HK1148525A1/xx not_active IP Right Cessation
-
2012
- 2012-01-11 US US13/348,380 patent/US8569340B2/en active Active
-
2013
- 2013-10-14 US US14/053,325 patent/US9174964B2/en active Active
-
2014
- 2014-05-13 AU AU2014202572A patent/AU2014202572B2/en not_active Ceased
-
2017
- 2017-04-27 AU AU2017202766A patent/AU2017202766B2/en not_active Ceased
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2010005298A (es) | Compuestos de carboxamida, sulfonamida y amina para trastornos metabolicos. | |
| MX338707B (es) | Compuestos heterociclicos activadores de proteina cinasa activada por 5'-amp (ampk) y metodos para emplearlos. | |
| MX2011007639A (es) | Compuestos de carboxamida y metodos para usar los mismos. | |
| ECSP088833A (es) | Inhibidores de 11-beta-hidroxiesteroide deshidrogenasa 1 | |
| DOP2007000078A (es) | Derivados de ciclohexilpirazol-lactama como inhibidores de 11-beta-hidroxiesteroide deshidrogenasa 1 | |
| EA201100503A1 (ru) | Глюкозидные производные и их применения | |
| ECSP088849A (es) | Pirrolidinonas sustituidas de pieridinil como inhibidores de 11-beta-hidroxiesteroide deshidrogenasa 1 | |
| BRPI0910182B8 (pt) | composto de fórmula (i), composição farmacêutica e uso de um composto | |
| EA200870216A1 (ru) | Амидо соединения и их применение в качестве лекарственных средств | |
| ATE482210T1 (de) | Oxadiazolderivate als s1p1-rezeptor-agonisten | |
| EA201071231A1 (ru) | Карбоксамидные соединения для лечения метаболических растройств | |
| ATE471311T1 (de) | Inhibitoren von11-beta- hydroxysteroiddehydrogenase 1 | |
| DK2134691T3 (da) | Quinolinonderivativer som parp- og tank-inhibitorer | |
| MA33776B1 (fr) | Dérivés arylecarbonyle et hétéroarylcarbonyle d'hexahydroindénopyridine et d'octahydrobenzoquinoline | |
| DK2029529T3 (da) | Substitueret pyrrolidinone som inhibitor af 11-beta-hydroxysteroiddehydrogenase 1 | |
| EA200870472A1 (ru) | Ингибиторы 11-бета-гидроксистероид-дегидрогеназы типа 1 | |
| EA200870474A1 (ru) | Ингибиторы 11-бета-гидроксистероид дегидрогеназы 1 | |
| BRPI1013821A8 (pt) | piridinas substituídas como antagonistas de ccr3. | |
| TW200716584A (en) | Dihydrobenzofuran derivatives and uses thereof | |
| TNSN08373A1 (en) | Azolopyrimidines as inhibitors of cannabinoid 1 activity | |
| CY1112429T1 (el) | Υποκατεστημενα παραγωγα σουλφοναμιδιου | |
| EA201070327A1 (ru) | Катехоламиновые производные и их пролекарства | |
| MX2011013884A (es) | Sulfonamidas heterociclicas, usos y composiciones farmaceuticas de las mismas. | |
| CR10371A (es) | Compuestos heterociclicos apropiados para tratar trastornos que responden a la moduilacion del receptor de serotonina 5ht6 | |
| EA201100502A1 (ru) | Гликозидные производные и их применения |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |